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In this era of a technological revolution in the health
arena, we are constantly being confronted with new
interventions for disease diagnosis, treatment, or rehabil-
itation. No health system is immune to challenges when it
comes to cover high demand for resources required for
these innovations which are increasingly more costly in
relation to limited resources.1 The ethical implications
and the balance between medical autonomy and the
resources needed to ensure sustainability of the health
system have been subjects of discussion in Colombia.2
Economic studies have been designed to support
decision-making by different players and users of health
systems, including policy-makers, health management
organization, managers of healthcare institutions, and
health professionals.2,3 Those studies take into consider-
ation information derived from other research, including
clinical trials or systematic reviews which offer informa-
tion regarding efficacy and clinical effectiveness and,
ultimately, provide results measured in monetary or
clinical terms.
A discussion on new technologies is always welcome
even if thosenewarrivals are not always better (in terms of
efficacy or clinical effectiveness) than the existing or usual
ones, but are almost always strongly advocated by
different players in the health system. However, economic
studies can also be used to show providers the favorable
economic rationale of the availability of a medication
which, although costly, is the only treatment option, even
in low incidence scenarios.
This issue of the Colombian Journal of Anesthesiology
features the article entitled “Cost–benefit relationship of
keeping dantrolene stocks from the point of view of
healthcare institutions” by Rincon-Valenzuela and
Gomez-Ardila.4 It is an important attempt at using
argumentative methodological and scientific strategies
to solve the problems of our health system and improve
communication with healthcare providers and decision-
makers. Their study shows that costs incurred to ensure
dantrolene stocks in healthcare institutions are, by far,
much lower than those needed to pay for the consequen-
ces of its unavailability which are, obviously, unquantifi-
able in terms of human lives.
Dantrolene availability in some institutions, or at least
for a cluster of institutions in geographic proximity, has
not been widely studied in Colombia. This is a flaw that
affects the quality and safety of anesthesia in Latin
American countries.5 Decision-makers in hospitals may
choose to not purchase and keep the drug in stock based
only on the incidence of malignant hyperthermia events
in patients receiving general anesthesia. The study by
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Rincon-Valenzuela and Gomez-Ardila shows clearly that
financial consequences derived from deaths related to the
occurrence of this event and their legal and administrative
implications are far greater than the thresholds consid-
ered. They point to the pressing need to initiate coordi-
nated action between healthcare institutions and
territorial entities to ensure the timely availability of this
drug.
Cost-effectiveness analyses are seldom found in Colom-
bian scientific literature on anesthesiology or other related
specialties. Worldwide, there is a clearly recognized need
for this type of research in anesthesiology, but there is still
a long way to go just as there are many other areas to
explore and strengthen, for example, health economics.6,7
Anesthetists are frequently faced with a choice between
different treatment strategies, but usually with little
information about a comparative cost–benefit relation-
ship. The article mentioned above may be an example to
be replicated in other equally critical settings of our
specialty or other related disciplines in Colombia.
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